ARA-290 (Cibinetide)

Overview

ARA-290, also known as cibinetide, is a synthetic peptide of 11 amino acids modeled on the tissue-protective domain of erythropoietin (EPO). It was engineered to keep EPO’s repair-promoting and anti-inflammatory signaling while removing its effect on red blood cell production.

It is most often discussed in the context of nerve health, where it has been studied for small-fiber neuropathy — including neuropathy associated with sarcoidosis — and for neuropathic symptoms in people with type 2 diabetes.

ARA-290 has been evaluated in early-phase human trials but is not approved by any major regulator for therapeutic use. It remains an investigational compound, and the evidence base is still limited.

How it works

ARA-290 selectively activates what researchers call the innate repair receptor (IRR), a receptor complex thought to combine the EPO receptor with the CD131 subunit. Native EPO also signals through this pathway, but ARA-290 was designed to engage tissue-protective signaling without triggering the erythropoietic effects that raise hematocrit.

Through this pathway, ARA-290 is reported in preclinical and early clinical work to reduce inflammation, protect cells from stress, and support regeneration of small nerve fibers. The precise mechanism in humans is not fully established.

Reported benefits

• Improvement in small-fiber neuropathy symptom scores (early clinical data)
• Increased corneal nerve fiber density, suggesting nerve-fiber regeneration (studied)
• Reduced neuropathic symptoms in type 2 diabetes (early clinical data)
• Anti-inflammatory and tissue-protective effects without raising red blood cell count

These are reported or studied effects from limited early-phase research, not guaranteed outcomes.

Considerations & side effects

Human data comes from small, early-phase trials, so the long-term safety profile of ARA-290 is not well characterized. In the studies conducted to date, it was generally well tolerated, with no significant changes in blood counts and mild reactions such as injection-site irritation among the effects reported.

Because ARA-290 is not an approved medicine, purity and quality vary in the research-chemical market. It is not a substitute for evaluation and treatment of neuropathy or any other condition by a qualified clinician.